The Chinese government is exploring the use of its corporate social credit system (SCS) as an intellectual property rights (IPR) enforcement tool. Under this system, placement on a new patent infringement blacklist released by China’s National Intellectual Property Administration (CNIPA) will, in turn, damage a company’s social credit rating. CNIPA is working closely with the State Administration for Market Regulation (SAMR), which will also rely on the SCS and other administrative measures...
China Market Intelligence
In July of last year, several arms of China's government released the first in a series of documents detailing the country’s latest national crime reduction campaign, encouraging stronger enforcement of existing laws and regulations. While several similar initiatives have occurred in the past, many US companies and risk management experts note that consistent rule-of-law type enforcement is the new normal.
President Xi recently pledged improvements to market access, IP protection, competitive markets, and monetary policy among other issues. Still, insufficient transparency surrounding opportunities for foreign companies to participate in projects continues to cloud companies’ strategic planning around BRI.
The increase of environmental enforcement actions following the implementation of China’s Environmental Protection Law in January 2015 has had a mixture of positive and negative effects on the business operations of US-China Business Council (USCBC) member companies.
Chinese Communist Party (CCP) officials are increasingly calling on companies to support the creation of party organizations among their employees.
In recent months regulators have announced that China will introduce punitive damages and more stringent penalties for certain intellectual property rights (IPR) violations, which would improve China’s intellectual property protection.
China has created a new agency with broadened investigatory authority to streamline anti-corruption efforts.
The General Office of the State Council’s legislative work plan for 2018 indicates that several policies affecting foreign companies may be revised this year, including foreign investment restri
China’s moves, including environmental shutdowns, to cut production capacity have reduced supply, raised prices, and in some cases disrupted supply chains.
Recently announced provincial reimbursement drug lists (PRDLs) provide possible new opportunities for US pharmaceutical companies seeking to expand market reach for their drugs in China.